Recursion Pharmaceuticals (RXRX)
(Real Time Quote from BATS)
$8.37 USD
+0.25 (3.08%)
Updated Apr 29, 2024 01:00 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
RXRX 8.37 +0.25(3.08%)
Will RXRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RXRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RXRX
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
RXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -26.36% in 4 Weeks, Here's Why Recursion Pharmaceuticals (RXRX) Looks Ripe for a Turnaround
All You Need to Know About Recursion Pharmaceuticals (RXRX) Rating Upgrade to Buy
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates
Other News for RXRX
The Top 3 Biotech Stocks to Buy in April 2024
Largest borrow rate increases among liquid names
Moderna and OpenAI in pact to fast-track drug development
Jim Cramer Says This Energy Stock Is 'Terrific,' Calls Casey's General Stores A 'Winner'
12 Health Care Stocks Moving In Wednesday's Pre-Market Session